All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional. If you are a patient or carer, please visit Know AML.

  TRANSLATE

The AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

The AML Hub
Brought to you by Scientific Education Support

The AML Hub is an independent medical education platform, sponsored by Daiichi Sankyo, Kura Oncology, Syndax, Abbvie, Thermo Fisher and Johnson & Johnson. Funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.

View all

Now you can support HCPs in making informed decisions for their patients

Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.

Find out more

4th AML Academy 2022

Share:

Sep 23, 2022

X post image

27 Apr 2023

Revisit this:
🎥#AMLAcademy22 | The AML Hub was pleased to speak to Nigel Russell, @GSTTnhs. We asked, what are the updates from the NCRI AML18 and AML19 clinical trials?

Click here 👉 https://t.co/vqndTfgPxJ.

#AMLsm #leusm

View on 

X post image

6 Feb 2023

🎥 #AMLAcademy22 | The AML Hub was pleased to speak to Nigel Russell, @GSTTnhs. We asked, What are the updates from the NCRI AML18 and AML19 clinical trials?
Click here to see what was said 👉 https://t.co/vqndTfgPxJ.
#AMLsm #leusm

View on 

X post image

9 Jan 2023

🎥 #AMLAcademy22 | The AML Hub was pleased to speak to @drpramilak. We asked, What does the future hold for patients with relapsed AML? Click here to see what she said 👉 https://t.co/h15woenO11.
#AMLsm #leusm

View on 

X post image

23 Sept 2022

CONGRESS #AMLAcademy22 | @jiri_pavlu, Lynn Quek, Sudhir Tauro and Rachel Protheroe debate the topic 'MRD measurement has no role in the routine management of adult patients with #AML outside the setting of NPM1-mutated disease and APL'

#AMLsm #Leukemia #medicalcongress

View on 

X post image

23 Sept 2022

CONGRESS #AMLAcademy22| @drpramilak @KingsCollegeNHS presents insightful findings from the 2022 paper by @KarilynLarkin et al 'High early death rates, treatment resistance and short survival of black adolescents and young adults with #AML'

#AMLsm #leukemia #medicalcongress

View on 

X post image

23 Sept 2022

CONGRESS #AMLAcademy22| Harmut Dohner @uni_ulm presents the David Grimwade Memorial Lecture on the updated changes in The International Consensus Classification of myeloid neoplasms and acute leukemias and the 2022 ELN recommendations of #AML.

#AMLsm #leukemia #medicalcongress

View on 

X post image

23 Sept 2022

CONGRESS #AMLAcademy22| @vicpotter123 @KingsCollegeNHS discusses which patients with #AML should undergo transplant and how. She highlights the use of MRD for guidance, post-transplant strategies and future challenges.

#AMLsm #leukemia #medicalcongress

View on 

X post image

23 Sept 2022

CONGRESS #AMLAcademy22| @anariomachin @QMBCI gives an overview on inherited myeloid malignancies and highlights important considerations for genetic testing and counselling.

#AML #AMLsm #leukemia #medicalcongress

View on 

X post image

22 Sept 2022

CONGRESS #AMLAcademy22| @pvyas_oxford @UniofOxford discusses the potential therapeutic applications of alloreactive T cells targeting leukaemia.

#AML #AMLsm #leukemia #medicalcongress

View on 

X post image

22 Sept 2022

CONGRESS #AMLAcademy22| @drpramilak @KingsCollegeNHS highlights several prospective trials primarily for patients with relapsed #AML. These include MDM2 inhibitors, cellular therapies and new conventional drug regimens.

#AMLsm #leukemia #medicalcongress

View on 

X post image

22 Sept 2022

CONGRESS #AMLAcademy22| @mikewdennis @TheChristieNHS discusses an aspirational portfolio of EVOLVE trials for frail patients with #AML.

#AMLsm #leukemia #medicalcongress

View on 

X post image

22 Sept 2022

CONGRESS #AMLAcademy22| Steve Knapper @cardiffuni discusses planned studies in fit newly diagnosed patients with #AML highlighting the VICTOR study for NMP1+ patients and the OVIATION study for APL patients.

#AMLsm #leukemia #medicalcongress

View on 

X post image

22 Sept 2022

CONGRESS #AMLAcademy22| @jloke1 @unibirmingham presents the PROPEL trial which looks to investigate the use of a multimodel personalised prehabilitation care package compared to best practice usual care for patients with #AML

#AMLsm #leukemia #medicalcongress

View on 

X post image

22 Sept 2022

CONGRESS #AMLAcademy22| @Wendyingramhaem, University Hospital Wales discusses the upcoming IMPACT portfolio and their objectives as randomised transplant trials including COSi, MoTD and AMADAEUS trial groups.

#AML #AMLsm #leukemia #medicalcongress

View on 

X post image

22 Sept 2022

CONGRESS #AMLAcademy22| Ian Thomas @cardiffuni discusses ensuring inclusion and diversity in AML trial recruitment, highlighting geographical spread and socioeconomic status as areas for further development.

#AML #AMLsm #leukemia #medicalcongress

View on 

X post image

22 Sept 2022

CONGRESS #AMLAcademy22| Nigel Russell @UoNFacultyMHS
presents key results from the AML19 trials, highlighting data on FLAG-ida and CPX-351 regimens and cytogenetic sub groups and their effects on patient outcomes.

#AML #AMLsm #leukemia #medicalcongress

View on 

X post image

22 Sept 2022

Check out the AML hub for congress cover on the 4th AML Academy 2022. #AMLAcademy22 https://t.co/UnxjNRv2Fa

View on 

<span>&nbsp;</span>

Please indicate your level of agreement with the following statements:

The content was clear and easy to understand

The content addressed the learning objectives

The content was relevant to my practice

I will change my clinical practice as a result of this content

More about...

NCRI AML Academy 2022AML Academy

This content is accurate as of the date of publication and is not updated retrospectively. Please refer to the latest available evidence, guidelines, and relevant regulatory information when making clinical decisions.

Clinical trials in AML - match patients with relevant trials

Newsletter

Subscribe to get the best content delivered to your inbox